Status:
COMPLETED
Effects of a Dopamine Agonist on Pharmacodynamics of Levodopa in Parkinson's Disease
Lead Sponsor:
Oregon Health and Science University
Collaborating Sponsors:
Boehringer Ingelheim
Conditions:
Parkinson's Disease
Eligibility:
All Genders
30-80 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to determine whether there is a benefit to giving a dopamine agonist to a patient with Parkinson's disease who is already being treated with levodopa.
Detailed Description
Patients with idiopathic PD based on London Brain Bank criteria as determined by an OHSU movement disorder specialist entered the study. They gave informed consent to a protocol approved by the Oregon...
Eligibility Criteria
Inclusion
- Age 30-80
- Idiopathic PD Hoehn \& Yahr stage 2-4,
- diagnosed by 2 of the 3 cardinal motor features
- Fluctuation response to levodopa
- Dyskinesia
- No other historical, laboratory or physical signs to suggest an alternate diagnosis
- No significant dementia, MMSE\>24
- On oral levodopa therapy
Exclusion
- dementia
- psychosis
- severe anxiety
- unstable cardiovascular disease
- uncontrolled hypertension
- history of cardiac arrhythmias
- active peptic ulcer disease
- anemia (HCT\<32%)
Key Trial Info
Start Date :
July 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2007
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT00666653
Start Date
July 1 2003
End Date
May 1 2007
Last Update
April 25 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oregon Health & Science University
Portland, Oregon, United States, 97239